

Soldano Ferrone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8570171/soldano-ferrone-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

199
papers

10,611
citations

58
h-index

98
g-index

220
ext. papers

12,470
ext. citations

7.5
avg. IF

6.17
L-index

#	Paper	IF	Citations
199	Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research.. <i>Frontiers in Veterinary Science</i> , 2022 , 9, 803093	3.1	0
198	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. 2022 , 10,		1
197	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab.. <i>Pathology and Oncology Research</i> , 2022 , 28, 1610297	2.6	2
196	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. 2022 , 10,		1
195	Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 577-588	6.1	5
194	A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 3757-3771	12.9	5
193	High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease. <i>Frontiers in Oncology</i> , 2021 , 11, 598001	5.3	0
192	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. <i>Cancers</i> , 2021 , 13,	6.6	3
191	Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. <i>Hepatology</i> , 2021 , 74, 550-565	11.2	5
190	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. <i>Frontiers in Neuroscience</i> , 2021 , 15, 662064	5.1	16
189	Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors. <i>Clinical Orthopaedics and Related Research</i> , 2021 , 479, 1373-1382	2.2	3
188	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 240	12.8	0
187	Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review. <i>JAMA Oncology</i> , 2021 , 7, 1051-1059	13.4	8
186	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 182-191	9.7	11
185	The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 903-912.e4	4.3	16
184	B7-H3: An Attractive Target for Antibody-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 1227-1235	11.9	44
183	The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. <i>Immunity</i> , 2021 , 54, 132-150.e9	32.3	14

182	B7-H3 targeted antibody-based immunotherapy of malignant diseases. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 587-602	5.4	6
181	A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. <i>Journal of Translational Medicine</i> , 2021 , 19, 17	8.5	4
180	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. <i>Cancer Immunology Research</i> , 2021 , 9, 441-453	12.5	7
179	Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 2837-2847	12.9	3
178	Proteomic profile of melanoma cell-derived small extracellular vesicles in patients' plasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , 2021 , 10, e12063	16.4	12
177	Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 3141-3153	12.9	12
176	Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. <i>Cells</i> , 2021 , 10,	7.9	2
175	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. <i>Trends in Cancer</i> , 2021 , 7, 1089-1101	12.5	7
174	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.. <i>JAMA Oncology</i> , 2021 ,	13.4	1
173	Improving the Clinical Significance of Preclinical Immunotherapy Studies through Incorporating Tumor Microenvironment-like Conditions. <i>Clinical Cancer Research</i> , 2020 , 26, 4448-4453	12.9	4
172	Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma 2020 , 8,		6
171	Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. <i>Cell Communication and Signaling</i> , 2020 , 18, 36	7.5	26
170	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020 , 18, 255	8.5	3
169	IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5520-5533	12.9	40
168	lncRNA CISAL Inhibits BRCA1 Transcription by Forming a Tertiary Structure at Its Promoter. <i>IScience</i> , 2020 , 23, 100835	6.1	13
167	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4266-4281	15.9	15
166	B7-H3-targeted Radioimmunotherapy of Human Cancer. <i>Current Medicinal Chemistry</i> , 2020 , 27, 4016-4038	13	3
165	HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. <i>Methods in Molecular Biology</i> , 2020 , 2055, 325-350	1.4	15

164	In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2020 , 146, 236-247	7.5	12
163	Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. <i>Scientific Reports</i> , 2020 , 10, 92	4.9	74
162	Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. <i>Frontiers in Immunology</i> , 2020 , 11, 561390	8.4	3
161	NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , 2020 , 12,	6.6	19
160	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy). <i>Journal of Translational Medicine</i> , 2020 , 18, 346	8.5	2
159	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. <i>Clinical Cancer Research</i> , 2020 , 26, 6321-6334	12.9	5
158	CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. <i>International Journal of Cancer</i> , 2020 , 146, 2531-2538	7.5	9
157	Potential Role of HLA Class I Antigens in the Glycolytic Metabolism and Motility of Melanoma Cells. <i>Cancers</i> , 2019 , 11,	6.6	3
156	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. <i>EBioMedicine</i> , 2019 , 47, 33-43	8.8	45
155	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , 2019 , 25, 2644-2655	12.9	34
154	Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919855491	5.4	10
153	Cancer Stem Cells: The Players of Immune Evasion from Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019 , 223-249	0.3	3
152	Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition. <i>Frontiers in Immunology</i> , 2019 , 10, 224	8.4	27
151	Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA Processing. <i>Clinical Cancer Research</i> , 2019 , 25, 3673-3688	12.9	35
150	High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. <i>Oncologist</i> , 2019 , 24, e275-e283	5.7	12
149	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. <i>Cancer Cell</i> , 2019 , 35, 221-237.e8	24.3	157
148	Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors. <i>Molecular Therapy - Oncolytics</i> , 2019 , 15, 30-37	6.4	10
147	Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation. <i>Theranostics</i> , 2019 , 9, 5739-5754	12.1	18

146	IL-15/B7-H3 TriKEs-Based Immunotherapy for Pancreatic Ductal Adenocarcinoma. <i>Journal of the American College of Surgeons</i> , 2019 , 229, S176	4.4	4
145	Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription. <i>Cancer Research</i> , 2019 , 79, 1069-1084	10.1	55
144	Novel ANO5 mutation c.1067G>T (p.C356F) identified by whole genome sequencing in a big family with atypical gnathodiaphyseal dysplasia. <i>Head and Neck</i> , 2019 , 41, 230-238	4.2	3
143	Constitutive and TNF β -inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	67
142	Defective HLA class I antigen processing machinery in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 999-1009	7.4	42
141	Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. <i>Journal of Extracellular Vesicles</i> , 2018 , 7, 1435138	16.4	132
140	Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. <i>Nuclear Medicine and Biology</i> , 2018 , 58, 67-73	2.1	26
139	HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. <i>Oral Oncology</i> , 2018 , 77, 92-97	4.4	6
138	Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	19
137	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 166-181	2.2	7
136	Methods for improving the immunogenicity and efficacy of cancer vaccines. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 765-784	5.4	8
135	Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. <i>Blood</i> , 2018 , 132, 701-701	2.2	5
134	Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12015-12015	2.2	1
133	Risk Prediction Model for Cisplatin-Associated Acute Kidney Injury. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2453-2454	2.2	2
132	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature 2018 , 6, 126		17
131	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018 , 9, 5097	17.4	13
130	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , 2018 , 53, 189-200	12.7	48
129	Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform. <i>Immunologic Research</i> , 2018 , 66, 584-604	4.3	9

128	Molecular and Functional Profiles of Exosomes From HPV(+) and HPV(-) Head and Neck Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2018 , 8, 445	5.3	33
127	B7-H3-targeted Pb radioimmunotherapy of ovarian cancer in preclinical models. <i>Nuclear Medicine and Biology</i> , 2017 , 47, 23-30	2.1	37
126	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. <i>OncImmunology</i> , 2017 , 6, e1171447	7.2	43
125	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. <i>Scientific Reports</i> , 2017 , 7, 2290	4.9	62
124	Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	140
123	Immunomodulating and Immuno-resistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. <i>Immunological Investigations</i> , 2017 , 46, 221-238	2.9	59
122	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017 , 7, 1420-1435	24.4	302
121	High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes. <i>Cellular Immunology</i> , 2017 , 320, 29-37	4.4	3
120	ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. <i>Scientific Reports</i> , 2017 , 7, 9687	4.9	11
119	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , 2017 , 409, 9-19	9.9	33
118	Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. <i>Journal of Immunological Methods</i> , 2017 , 450, 73-80	2.5	23
117	CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 707-716	12.9	74
116	Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. <i>Frontiers in Immunology</i> , 2017 , 8, 457	8.4	30
115	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 37646-37656	3.3	17
114	Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. <i>Oncotarget</i> , 2017 , 8, 113837-113846	3.3	12
113	Intact APM and PD-1:PD-L1 pathway upregulation in HIV-infected head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6058-6058	2.2	
112	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 470-8	12.9	124
111	Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. <i>Oral Oncology</i> , 2016 , 58, 52-8	4.4	37

110	Antitumor Activity of BRAF Inhibitor and IFN[Combination in BRAF-Mutant Melanoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	29
109	Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. <i>Oncotarget</i> , 2016 , 7, 2070-9	3.3	9
108	Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. <i>Oncotarget</i> , 2016 , 7, 7390-402	3.3	59
107	AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. <i>Oncotarget</i> , 2016 , 7, 60872-60884	3.3	6
106	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2016 , 23, 609-617	3.1	16
105	Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 5229-5237	12.9	85
104	CSPG4 as a prognostic biomarker in chordoma. <i>Spine Journal</i> , 2016 , 16, 722-7	4	21
103	HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. <i>European Journal of Immunology</i> , 2016 , 46, 409-19	6.1	23
102	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 1339-50	6.4	16
101	CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015 , 75, 2200-10	10.1	175
100	Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. <i>Journal of Biological Chemistry</i> , 2015 , 290, 26562-75	5.4	45
99	Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. <i>Oncolimmunology</i> , 2015 , 4, e1023975	7.2	20
98	Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. <i>Oncology Research</i> , 2015 , 22, 117-21	4.8	3
97	STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. <i>Cancer Immunology Research</i> , 2015 , 3, 936-45	12.5	54
96	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. <i>Molecular Oncology</i> , 2015 , 9, 1982-93	7.9	14
95	Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. <i>Gynecologic Oncology</i> , 2014 , 132, 203-10	4.9	30
94	T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. <i>Clinical Cancer Research</i> , 2014 , 20, 962-71	12.9	58
93	Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. <i>Seminars in Oncology</i> , 2014 , 41, 685-99	5.5	8

92	Therapeutic monoclonal antibodies: introduction. <i>Seminars in Oncology</i> , 2014 , 41, 556-8	5.5	3
91	Programmed cell death ligand 1 expression in osteosarcoma. <i>Cancer Immunology Research</i> , 2014 , 2, 690-698	6.2	135
90	Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. <i>Journal of Immunology</i> , 2014 , 192, 523-32	5.3	80
89	Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2014 , 85, 953-61	4.6	10
88	Ipilimumab in the treatment of metastatic melanoma: management of adverse events. <i>OncoTargets and Therapy</i> , 2014 , 7, 203-9	4.4	74
87	NK cells and T cells cooperate during the clinical course of colorectal cancer. <i>OncoImmunology</i> , 2014 , 3, e952197	7.2	73
86	Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , 2014 , 5, 5639	17.4	77
85	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells 2014 , 2, 25		82
84	Genetic evolution of T-cell resistance in the course of melanoma progression. <i>Clinical Cancer Research</i> , 2014 , 20, 6593-604	12.9	106
83	CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. <i>Clinical Cancer Research</i> , 2014 , 20, 3753-62	12.9	51
82	Dendritic cell maturation in HCV infection: altered regulation of MHC class I antigen processing-presenting machinery. <i>Journal of Hepatology</i> , 2014 , 61, 242-51	13.4	12
81	HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. <i>Neoplasia</i> , 2014 , 16, 31-42	6.4	72
80	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 230-230	2.2	2
79	Blocking the formation of radiation-induced breast cancer stem cells. <i>Oncotarget</i> , 2014 , 5, 3743-55	3.3	77
78	Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. <i>Methods in Molecular Biology</i> , 2014 , 1102, 523-35	1.4	12
77	Dose-seeking and efficacy study of combination BRAFi and high-dose IFN (HDI) for therapy of advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9110-TPS9110	2.2	
76	Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS9105-TPS9105	2.2	
75	Emerging BRAF inhibitors for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 431-43	3.7	5

74	EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. <i>Oncolimmunology</i> , 2013 , 2, e27215	7.2	27
73	SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. <i>Clinical Cancer Research</i> , 2013 , 19, 798-808	12.9	58
72	LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. <i>Clinical Cancer Research</i> , 2013 , 19, 1816-26	12.9	57
71	Multidisciplinary approach to patient with malignant melanoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013 , 13, 887-900	2.2	3
70	Tumor Antigen-Specific Monoclonal Antibody-Based Immunotherapy, Cancer Initiating Cells and Disease Recurrence. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013 , 25-47	0.3	4
69	A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 127, 420-5	4.9	55
68	Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. <i>International Journal of Oncology</i> , 2012 , 40, 965-74	4.4	36
67	CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. <i>Clinical Cancer Research</i> , 2012 , 18, 5352-63	12.9	57
66	Melanoma cells inhibit NK cell functions. <i>Cancer Research</i> , 2012 , 72, 5428-9; author reply 5430	10.1	47
65	CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011 , 24, 1148-57	4.5	109
64	Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. <i>Veterinary Journal</i> , 2011 , 190, e26-e30	2.5	30
63	Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. <i>Clinical Cancer Research</i> , 2011 , 17, 6174-84	12.9	135
62	Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. <i>Clinical Cancer Research</i> , 2011 , 17, 2668-78	12.9	51
61	Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. <i>Cancer Research</i> , 2011 , 71, 7410-22	10.1	47
60	Hidden immunotherapy targets challenge dogma. <i>Science Translational Medicine</i> , 2011 , 3, 99ps38	17.5	10
59	A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. <i>Cancer Research</i> , 2010 , 70, 3027-33	10.1	58
58	Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. <i>Clinical Cancer Research</i> , 2010 , 16, 11-20	12.9	57
57	CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1496-512	9.7	117

56	Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. <i>Clinical Cancer Research</i> , 2010 , 16, 800-13	12.9	244
55	Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunescape. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4390-9	2.2	243
54	Functional and clinical relevance of chondroitin sulfate proteoglycan 4. <i>Advances in Cancer Research</i> , 2010 , 109, 73-121	5.9	83
53	Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 529-40	7.4	72
52	Response to the letter to the editors by Ottaiano et al.: Cetuximab-dependent ADCC in cancer: dream or reality? <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1609-1610	7.4	
51	Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 1853-64	7.4	139
50	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1251-63	15.9	260
49	Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. <i>Cancer Research</i> , 2008 , 68, 8066-75	10.1	85
48	Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 197-206	7.4	134
47	Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. <i>Surgery</i> , 2007 , 141, 41-50	3.6	80
46	Immune selective pressure and HLA class I antigen defects in malignant lesions. <i>Cancer Immunology, Immunotherapy</i> , 2007 , 56, 227-36	7.4	89
45	Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 3890-5	12.9	174
44	A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. <i>Expert Review of Dermatology</i> , 2006 , 1, 805-823		2
43	HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. <i>Cancer Research</i> , 2006 , 66, 9281-9	10.1	146
42	The Effects of Anti-High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAb) Against 11q23 Positive Acute Leukemia Cells.. <i>Blood</i> , 2006 , 108, 4550-4550	2.2	1
41	Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. <i>Oncogene</i> , 2005 , 24, 4634-44	9.2	81
40	A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. <i>Journal of Immunological Methods</i> , 2005 , 299, 139-51	2.5	55
39	Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. <i>Cancer Research</i> , 2005 , 65, 6976-83	10.1	16

38	Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. <i>Clinical Cancer Research</i> , 2005 , 11, 2552-60	12.9	194
37	Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. <i>Advances in Cancer Research</i> , 2005 , 93, 189-234	5.9	86
36	Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. <i>Journal of Immunology</i> , 2005 , 174, 1462-71	5.3	86
35	Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. <i>Journal of Immunology</i> , 2005 , 174, 7104-10	5.3	21
34	Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. <i>Journal of Cell Biology</i> , 2004 , 165, 881-91	7.3	116
33	Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?. <i>Blood</i> , 2004 , 103, 3122-30	2.2	89
32	Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. <i>Critical Reviews in Immunology</i> , 2004 , 24, 267-96	1.8	145
31	The Antileukemic Effect of NK and NK-T Cells Against Chronic Myelogenous Leukemia Is Dominated by Interactions between Activating Molecules and Their Ligands Which Overcome Inhibitory KIR-MHC Class I Interaction.. <i>Blood</i> , 2004 , 104, 2948-2948	2.2	
30	Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. <i>Journal of Immunology</i> , 2003 , 171, 1918-26	5.3	144
29	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. <i>Cancer</i> , 2003 , 97, 2203-11	6.4	31
28	Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. <i>Clinical Cancer Research</i> , 2003 , 9, 1721-7	12.9	77
27	Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. <i>Clinical Cancer Research</i> , 2003 , 9, 4043-51	12.9	59
26	Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression?. <i>Cancer Journal (Sudbury, Mass)</i> , 2002 , 8, 369-70	2.2	1
25	Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. <i>Cancer</i> , 2001 , 92, 369-76	6.4	142
24	TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. <i>International Journal of Cancer</i> , 2001 , 95, 23-8	7.5	56
23	Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. <i>International Journal of Cancer</i> , 2000 , 89, 153-9	7.5	23
22	Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2000 , 49, 314-8	7.4	27
21	Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. <i>Journal of Immunology</i> , 2000 , 165, 3275-83	5.3	43

20	Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. <i>Advances in Immunology</i> , 2000 , 74, 181-273	5.6	863
19	Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. <i>Journal of Experimental Medicine</i> , 1999 , 190, 205-15	16.6	89
18	Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. <i>Journal of Investigative Dermatology</i> , 1999 , 112, 744-50	4.3	16
17	HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. <i>Trends in Molecular Medicine</i> , 1999 , 5, 178-86		279
16	Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. <i>American Journal of Pathology</i> , 1999 , 154, 745-54	5.8	220
15	Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. <i>Trends in Immunology</i> , 1995 , 16, 487-94		413
14	Radioimmuno-detection of Melanoma: Preliminary Results of a Prospective Study. <i>International Journal of Biological Markers</i> , 1986 , 1, 47-54	2.8	18
13	Distribution of a cross-species melanoma-associated antigen in normal and neoplastic human tissues. <i>Journal of Investigative Dermatology</i> , 1985 , 85, 340-6	4.3	12
12	Analysis of the NIH workshop monoclonal antibodies to human melanoma antigens. <i>Hybridoma</i> , 1982 , 1, 473-82		16
11	Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. <i>Transplantation</i> , 1982 , 34, 18-23	1.8	88
10	Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. <i>International Journal of Cancer</i> , 1981 , 28, 293-300	7.5	221
9	Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6 and Q5/13) on human Ia-like alloantigens and on their subunits. <i>Immunogenetics</i> , 1981 , 12, 175-82	3.2	38
8	Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: analysis of the role of Ia-like antigens with monoclonal antibodies. <i>Immunogenetics</i> , 1981 , 12, 267-74	3.2	50
7	Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives: reactivity with the HLA antigenic molecular complex. <i>Arthritis and Rheumatism</i> , 1980 , 23, 265-72		37
6	Structural polymorphism of human DR antigens. <i>Nature</i> , 1979 , 279, 436-7	50.4	64
5	Sera from volunteers immunized by planned blood transfusions as source of DR cytotoxic typing reagents. <i>Immunological Investigations</i> , 1979 , 8, 93-106		3
4	The major portion of rabbit antibody to serum HLA-A9 antigens is directed to allospecificity. <i>Tissue Antigens</i> , 1978 , 12, 153-5		1
3	Rabbit complement in the lymphocytotoxicity test. <i>Tissue Antigens</i> , 1977 , 9, 223-6		11

2	Association of HL-A antigens and \bar{D} -microglobulin at the cellular and molecular level. <i>Immunogenetics</i> , 1975 , 2, 183-197	3-2	54
1	Activation of the complement system by H-2 alloantisera: Differential susceptibility to lysis of thymocytes and lymphocytes. <i>Immunogenetics</i> , 1975 , 2, 199-203	3-2	1